CDMOs offering Topical & Semi-Solid Manufacturing with Small Molecule

Topical & Semi-Solid Manufacturing combined with Small Molecule is a common shortlist filter for sponsors evaluating CDMO partners. This explore page lists organizations that publicly map to both dimensions, so you can move from taxonomy browsing to a tighter candidate set without rebuilding filters from scratch.

Profiles here are fit-first: open each listing for scope, geography, regulatory posture, and provenance-backed facts. The directory does not rank these rows as a single "best" answer — use them to assemble a right-sized outreach list for your program stage and quality bar.

When you need adjacent criteria (indications, claim status, or cross-category search), continue to the main search experience and layer filters on top of this service × modality starting point.

Auto-generated by BioBM Editorial AI.

Matching companies

Adragos Pharma
Global CDMO headquartered in Munich offering end-to-end development and manufacturing for small molecules and biologics, including sterile/non-sterile liquids, solids, semi-solids, lyophilization, and prefilled syringes across seven facilities in Europe and Japan.
Akums Drugs and Pharmaceuticals Ltd.
India's largest CDMO with 15+ state-of-the-art facilities and 30% domestic market share, manufacturing 4,100+ formulations across tablets, capsules, injectables, APIs, and specialty dosage forms under WHO-GMP, USFDA, EU-GMP, and TGA compliance.
Bend Bioscience
U.S. pharmaceutical CDMO offering design, development, and manufacturing of oral solid and liquid dosage forms, from early formulation to commercial-scale production across three domestic locations.
Catalent
Global CDMO providing end-to-end contract development and manufacturing for pharma, biotech, and consumer health. Delivers 60+ billion doses annually across small molecules, biologics, cell & gene therapies, and clinical supply.
Delpharm
Top-5 global CDMO with 18 production sites across Europe and North America, specializing in solid, semi-solid, non-sterile and sterile liquid dosage forms including prefilled syringes, nasal sprays, and injectables; capacity to produce over 300 million units annually.
Halo Pharma
Halo Pharma provides end-to-end pharmaceutical development and manufacturing for small molecule therapeutics across solids, semi-solids, oral liquids, and sterile injectables, with two North American cGMP facilities and an accelerated 16–20 week tech transfer program.
Pharmaron
Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Syngene International
Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
UPM Pharmaceuticals
Independent, family-owned CDMO specializing in oral solids, semi-solids, and controlled-substance manufacturing with 475,000 sq ft cGMP facility in Bristol, TN; over 80 products commercialized.

Markdown mirror: /explore/svc_topical_dosage/mod_small_molecule.md